Zacks Research Has Pessimistic Outlook of IQVIA Q1 Earnings

IQVIA Holdings Inc. (NYSE:IQV) – Analysts at Zacks Research cut their Q1 2025 earnings per share estimates for IQVIA in a note issued to investors on Thursday, November 21st. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $2.34 per share for the quarter, down from their previous estimate of $2.49. The consensus estimate for IQVIA’s current full-year earnings is $10.17 per share. Zacks Research also issued estimates for IQVIA’s Q2 2025 earnings at $2.59 EPS and FY2025 earnings at $10.58 EPS.

Several other equities research analysts have also issued reports on the stock. Truist Financial decreased their price target on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. The Goldman Sachs Group dropped their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Evercore ISI reduced their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Finally, BTIG Research lowered their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a report on Friday, November 1st. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $201.82 on Monday. The company’s 50 day simple moving average is $222.67 and its 200 day simple moving average is $227.16. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA has a 1 year low of $187.62 and a 1 year high of $261.73. The stock has a market capitalization of $36.63 billion, a price-to-earnings ratio of 26.49, a price-to-earnings-growth ratio of 2.03 and a beta of 1.51.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This represents a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of IQV. Capital Performance Advisors LLP purchased a new stake in IQVIA in the 3rd quarter valued at about $27,000. Park Place Capital Corp purchased a new stake in shares of IQVIA during the third quarter valued at approximately $28,000. Versant Capital Management Inc lifted its holdings in IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares during the period. Opal Wealth Advisors LLC purchased a new position in IQVIA in the second quarter worth $27,000. Finally, Itau Unibanco Holding S.A. bought a new position in IQVIA in the 2nd quarter valued at $29,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.